111 Inc. receives management-led privatization offer
Drug seller 111 Inc. (YI.US) on Thursday announced its revenue contracted and its loss widened in the second quarter as it transitions to a new asset-light business model. The same…
Legend Biotech names new CEO
Cancer treatment maker Legend Biotech Corp. (LEGN.US) announced its appointment of a new CEO on Tuesday, a month and a half after the sudden departure of its longtime chief executive…
Edge Medical eyes Mainland listing months after Hong Kong IPO
Surgical robot maker Shenzhen Edge Medical Co. Ltd. (2675.HK) announced last Friday that it is exploring a second listing on China’s domestic A-share markets in Shanghai and Shenzhen, just months…
Burning Rock’s revenue dips on weakness in R&D, central lab businesses
Cancer testing company Burning Rock Biotech Ltd. (BNR.US) on Thursday reported its revenue fell 9.3% year-on-year to 135 million yuan ($20.1 million) in the second quarter, as an increase for…
Medcaptain plunges in trading debut for heavily oversubscribed IPO
Medical device maker Shenzhen Medcaptain Technology Co. Ltd. (2041.HK) plunged in its Hong Kong trading debut on Monday, opening 35% lower before stabilizing to close at HK$10.10 by the midday…
Jinxin Fertility swings back to the black as margins improve and U.S. unit gains traction
The assisted reproduction services provider posted a net profit of 110 million yuan in the first half of 2026, as its revenue rose 6.6% By Teri Yu Jinxin Fertility Group…
China pivots to ‘hard tech’ and global branding: Frost & Sullivan Summit
As global trade becomes fragmented, Chinese enterprises are embracing hard technology and non-market strategies to build durable, world-class brands By Da Cheung Chinese enterprises are adapting to a shifting global…
